Search - tctmd.com

Displaying 41 - 60 of 89

Sort: Relevancy | Date

Presentation TCT 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presenter: Francesco Franchi

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Insights From SMART CHOICE

Presenter: Joo-Yong Hahn

September 26, 2019

Presentation TCT 2019

Insights From STOP DAPT-2

Presenter: Takeshi Kimura

September 26, 2019

Presentation TCT 2019

Insights From TWILIGHT

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

Insights From GLOBAL LEADERS and GLASSY

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Presenter: Robert Byrne

September 26, 2019

Presentation TCT 2019

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

Presenter: Amit Vora

September 26, 2019

News Conference News TCT 2018

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

Todd Neale

September 24, 2018

News Conference News TCT 2018

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

Michael O'Riordan

September 21, 2018

Presentation TCT 2018

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Presenter: George D. Dangas, Germano Di Sciascio, Anne Tavenier

September 21, 2018

Presentation TCT 2017

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Fabiana Rollini

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Somjot S. Brar

October 30, 2017

Presentation TCT 2017

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Presenter: John A. Bittl, Freek W.A. Verheugt, Dimitrios Alexopoulos

October 30, 2017

Presentation TCT 2017

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Presenter: Davide Capodanno, David Hildick-Smith, Marco Zimarino

October 30, 2017

News Conference News TCT 2017

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Todd Neale

October 30, 2017

Presentation TCT 2016

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Presenter: Roxana Mehran, Ferdinando Varbella, Dominick J. Angiolillo

November 01, 2016

Advertisement

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Insights From SMART CHOICE

Insights From STOP DAPT-2

Insights From TWILIGHT

Insights From GLOBAL LEADERS and GLASSY

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

OAC-ALONE: No Clear Answer for Best Therapy Beyond 1 Year After PCI in A-fib Patients

EXCEL Deep Dive: Repeat Revascularization, Medical Therapy, and Anemia All Impact Patient Prognosis

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Switching Between Oral P2Y12 Receptor Inhibitors: When and How?

Crushing and Chewing Oral P2Y12 Receptor Inhibitors: Pharmacodynamic and Clinical Impact

Debate: Making the Case for Not Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Debate: Making the Case for Pretreating ACS patients With Oral P2Y12 Receptor Inhibitors!

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Help for Clinicians Whose Patients Need to Switch P2Y12 Inhibitors

Intravenous P2Y12 Receptor Inhibitors Transitioning to a Potent Oral Anti-platelet Agent if PCI Is Performed Is Optimal Treatment in NSTE-ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content